Reaction

Cholecystitis Infective reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,735 reports · 61 co-occurring drugs

As of the last recalculation, Cholecystitis Infective appears in 2,735 FAERS reports alongside 61 co-occurring drug terms. The strongest observed disproportionality signal is TEDUGLUTIDE (PRR 14.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Teduglutide	26	14.8	14.8
Drospirenone And Ethinyl Estradiol	70	12.3	12.4
Octreotide Acetate	44	11.1	11.1
Clobazam	30	9.4	9.5
Lanreotide Acetate	9	8.8	8.8
Lenvatinib	37	8.7	8.7
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	30	7.4	7.4
Oxazepam	20	7.1	7.1
Cholestyramine	11	6.9	7.0
Liothyronine Sodium	7	6.1	6.1
Basiliximab	9	5.8	5.8
Pramipexole	11	5.5	5.5
Everolimus Tablets	12	5.5	5.5
Fenofibrate	22	4.8	4.8
Risankizumab-Rzaa	50	4.7	4.7
Sunitinib Malate	24	4.7	4.7
Valsartan And Hydrochlorothiazide	8	4.5	4.5
Tramadol Hydrochloride	22	4.5	4.5
Oral Semaglutide	40	4.2	4.2
Epoprostenol	7	4.1	4.1
Cladribine	5	4.0	4.0
Ibrutinib	41	3.9	3.9
Lisinopril And Hydrochlorothiazide Tablets	4	3.9	3.9
Interferon Beta-1A	94	3.8	3.8
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose	4	3.7	3.7
Obinutuzumab	8	3.7	3.7
Bendamustine Hcl	7	3.4	3.4
Nintedanib	14	3.4	3.4
Regorafenib	5	3.3	3.3
Dabigatran Etexilate Mesylate	31	3.3	3.3
Liraglutide	21	3.3	3.3
Ocrelizumab	26	3.2	3.2
Ticagrelor	13	3.1	3.1
Sofosbuvir	8	3.1	3.1
Carbidopa And Levodopa	19	3.1	3.1
Dabigatran Etexilate	31	3.1	3.1
Budesonide, Glycopyrrolate, And Formoterol Fumarate	4	2.9	2.9
Temozolomide	8	2.9	2.9
Venetoclax	23	2.9	2.9
Exenatide	19	2.8	2.8
Ustekinumab	36	2.7	2.7
Orlistat	9	2.6	2.6
Treprostinil	43	2.6	2.6
Tafamidis	4	2.6	2.6
Tirzepatide	54	2.6	2.6
Agalsidase Beta	3	2.5	2.5
Cabozantinib	15	2.4	2.4
Ofatumumab	10	2.3	2.3
Natalizumab	54	2.3	2.3
Benralizumab	6	2.3	2.3
Ambrisentan	36	2.2	2.2
Patiromer	4	2.2	2.2
Trifluridine And Tipiracil	3	2.1	2.1
Diroximel Fumarate	3	1.9	1.9
Lenalidomide	97	1.8	1.8
Dulaglutide	18	1.5	1.5
Pirfenidone	8	1.5	1.5
Sarilumab	5	1.4	1.4
Pomalidomide	19	1.4	1.4
Esketamine Hydrochloride	3	1.3	1.3
Pimavanserin Tartrate	8	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.